Study of Burst Stimulation-Guided Ablation to Improve Outcomes in Paroxysmal Atrial Fibrillation Patients Undergoing Catheter Treatment

What this Trial Is About

Paroxysmal atrial fibrillation PAF is a common heart rhythm disorder linked to serious health risks like stroke and heart failure. Studies in China show rising rates among people aged 60 and older. While catheter ablation focusing on pulmonary vein isolation PVI is a standard treatment for drug-resistant PAF, recurrence rates remain high. Researchers are investigating additional factors, like non-pulmonary vein triggers and atrial remodeling, to improve treatment. This trial explores a novel ablation strategy combining burst stimulation and individualized linear ablation to reduce PAF recurrence and improve patient outcomes. The study compares two groups one receiving pulmonary vein isolation plus superior vena cava isolation SVCI and the other receiving the same plus burst stimulation with individualized linear ablation. The additional procedures aim to target atrial arrhythmias induced during the ablation process. This prospective, multicenter, randomized controlled trial will evaluate the safety and effectiveness of this approach to optimize catheter ablation for PAF. Participants aged 18 to 80 with documented paroxysmal atrial fibrillation scheduled for their first radiofrequency catheter ablation will be enrolled. They will be followed for 12 months with assessments at 1, 3, 6, and 12 months to measure recurrence rates, adverse cardiovascular events, arrhythmia induction during the procedure, and complications. The study includes monitoring quality of life and atrial fibrillation burden to provide a comprehensive evaluation of this personalized ablation method.

Burst Stimulation for Paroxysmal Atrial Fibrillation